UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
FORM 4
[ ] Check this box if no longer OMB APROVAL
subject to Section 16. Form 4 or OMB NUMBER: 3235-0287
Form 5 obligations may continue. Expires: September 30, 2000
See Instruction 1(b). Estimated average burden
hours per response........0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935
or Section 30(f) of the Investment Company Act of 1940
(Print or Type Responses)
1. Name and Address of Reporting Person*
Morgan Stanley Dean Witter & Co.
- -----------------------------------------------------------------------------
(Last) (First) (Middle)
1585 Broadway
- ----------------------------------------------------------------------------
(Street)
New York NY 10036
- -----------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Allscripts Healthcare Solutions, Inc. (MDRX)
- -----------------------------------------------------------------------------
3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)
- -----------------------------------------------------------------------------
4. Statement for Month/Year
05/01
- -----------------------------------------------------------------------------
5. If Amendment, Date of Original (Month/Day/Year)
- -----------------------------------------------------------------------------
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Director X 10% Owner
--- ---
Officer (give title below) Other (specify below)
--- ---
- ----------------------------------------------------------------------------
7. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
- ----
X Form filed by More than One Reporting Person
- ----
Table I -- Non-Derivative Securities Acquired, Disposed of or
Beneficially Owned
1. Title of Security 2. Trans- 3. Trans- 4. Securities Acquired 5. Amount of Securities 6. Ownership 7. Nature of
(Instr. 3) action action (A) or Disposed of Beneficially Owned Form: Direct Indirect
Date Code (D) (Instr. 3, 4 at End of Month (D) or In- Beneficial
(Instr.8) and 5) (Instr. 3 and 4) direct (I) Ownership
(Month/ (Instr. 4) (Instr. 4)
Day/ (A) or
Year) Code V Amount (D) Price
- ------------------------- --------- ---- --- ------- --- --------- -------------------- -------------- -------------
Common Stock 05/01/01 J(2) 1,300,000 D 0 3,954,063 I(4) through
participation
Common Stock 05/01/01 J(3) 66,527 A 0 3,954,063 I(4) through
participation
Common Stock 05/24/01 S(5) 14,900 D $4.44 3,954,063 I(4) through
partnerships
Common Stock 05/25/01 S(5) 12,500 D $4.24 3,954,063 I(4) through
partnerships
Common Stock 05/29/01 S(5) 39,127 D $4.26 3,954,063 I(4) through
partnerships
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
4(b)(v).
(Over)
SEC 1474 (7-96)
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of 2. Conversion or 3. Transaction Date 4. Transaction 5. Number of 6. Date Exercisable and
Derivative Exercise Price (Month/Day/Year) Code Derivative Expiration Date
Security of Derivative (Instr. 8) Securities (Month/Day/Year)
(Instr. 3) Security Acquired (A)
or Disposed of
(D) (Instr. 3,
4 and 5)
Date Expiration
Code V (A) (D) Exercisable Date
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of 7. Title and Amount of 8. Price of 9. Number of 10. Ownership 11. Nature of
Derivative Underlying Securities Derivative derivative Form of Indirect
Security (Instr. 3 and 4) Security Securities Derivative Beneficial
(Instr. 3) (Instr. 5) Beneficially Security: Ownership
Amount Owned at End Direct (D) (Instr. 4)
or of Month or Indirect
Number (Instr. 4) (I)
of (Instr. 4)
Title Shares
- ------------------------------------------------------------------------------------------------------------------------------------
- --------------------------------
Explanation of Responses:
(1) Please see attached Joint Filer Information. /s/ Peter Vogelsang
--------------------------------------------
(2) Morgan Stanley Venture Partners III, L.P., Morgan Stanley Venture **Signature of Reporting Person
Investors III, L.P. and The Morgan Stanley Venture Partners Entrepreneur By: Peter Vogelsang, authorized signatory
Fund, L.P. (collectively, the "Funds"), of which Morgan Stanley Venture for Morgan Stanley Dean Witter & Co.
Partners III, L.L.C. is a general partner (the "General Partner"), made an
in-kind distribution of 1,300,000 shares of Common Stock (the
"Distribution"). The reported securities were distributed to the partners /s/ Debra Abramovitz
of the Funds in proportion to their partnership interests in the Funds. --------------------------------------------
**Signature of Reporting Person
(3) Morgan Stanley Venture Capital III, Inc. ("MSVC III, Inc.") received By: Debra Abramovitz, Vice President and
66,527 shares of Common Stock in the Distribution. Treasurer of Morgan Stanley Venture
Capital III, Inc., institutional managing
(4) The reported securities are owned directly by the Funds. MSVC III, Inc., member of the General Partner of the
as an institutional managing member of the General Partner, and Morgan Funds, for each of these entities.
Stanley Dean Witter & Co., as the ultimate parent company of MSVC III,
Inc., each disclaim beneficial ownership of the securities except to the
extent of their pecuniary interests therein. 06/08/01
-------------
(5) MSVC III, Inc. sold the shares of Common Stock on the dates indicated. Date
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
space provided is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB Number.
Page 2
SEC 1474 (7-96)
JOINT FILER INFORMATION
Each of the following joint filers has designated Morgan Stanley Dean
Witter & Co. ("MSDW") as the "Designated Filer" for purposes of the attached
Form 4:
(1) Morgan Stanley Venture Capital III, Inc. ("MSVC III, Inc.")
1221 Avenue of the Americas
New York, New York 10020
(2) Morgan Stanley Venture Partners III, L.L.C. ("MSVP III, L.L.C.")
1221 Avenue of the Americas
New York, New York 10020
(3) Morgan Stanley Venture Partners III, L.P. ("MSVP III, L.P.")
1221 Avenue of the Americas
New York, New York 10020
(4) The Morgan Stanley Venture Partners Entrepreneur Fund, L.P.
(the "Entrepreneur Fund")
1221 Avenue of the Americas
New York, New York 10020
(5) Morgan Stanley Venture Investors III, L.P. ("MSVI III, L.P.")
1221 Avenue of the Americas
New York, New York 10020
Issuer & Ticker Symbol: Allscripts Healthcare Solutions, Inc. (MDRX)
Dates of Events Requiring Statement: 05/01/01, 05/24/01, 05/25/01,
05/29/01
Signature: /s/ Peter Vogelsang
-------------------------------------------------------------
By: Peter Vogelsang, as authorized signatory for MSDW.
Signature: /s/ Debra Abramovitz
-------------------------------------------------------------
By: Debra Abramovitz, as Vice President and Treasurer of
MSVC III, Inc., the institutional managing member of
MSVP III, L.L.C., the General Partner of MSVP III, L.P.,
the Entrepreneur Fund and MSVI III, L.P.
